Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$64 Mln
Net Profit (TTM)
$-453 Mln
ROE
-3.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4
Industry P/E
--
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
-0.1
Book Value
$--
EPS
$-1.1
Face value
--
Shares outstanding
551,281,154
CFO
$-1,277.37 Mln
EBITDA
$-1,395.64 Mln
Net Profit
$-2,013.72 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sorrento Therape (SRNE)
| -- | -- | -- | -- | -79.5 | -79.4 | -52.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Sorrento Therape (SRNE)
| -80.9 | -31.9 | 101.9 | 40.8 | -36.7 | -22.4 | -43.7 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sorrento Therape (SRNE)
|
0.0 | 1.3 | 64.3 | -534.2 | -566.3 | -- | -- | 4.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell... therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. Read more
Chairman, Pres & CEO
Dr. Henry H. Ji Ph.D.
Chairman, Pres & CEO
Dr. Henry H. Ji Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sorrento Therape (SRNE) is $0.00 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Sorrento Therape (SRNE) has given a return of -79.5% in the last 3 years.
Since, TTM earnings of Sorrento Therape (SRNE) is negative, P/E ratio is not available.
The P/B ratio of Sorrento Therape (SRNE) is 4.01 times as on 27-Mar-2026, a 2 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.67
|
-17.22
|
|
2021
|
-3.24
|
17.81
|
|
2020
|
-5.56
|
12.18
|
|
2019
|
-1.72
|
18.84
|
|
2018
|
-1.44
|
1.41
|
The 52-week high and low of Sorrento Therape (SRNE) are Rs 0.01 and Rs 0.01 as of 03-Apr-2026.
Sorrento Therape (SRNE) has a market capitalisation of $ 1 Mln as on 27-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sorrento Therape (SRNE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.